Correlation Between CYP2C19 Genotype, Level Of Clopidogrel Metabolite And Platelet Inhibition Status
1 other identifier
observational
500
1 country
1
Brief Summary
The aim of this study is to check correlation between CYP2C19 genotype level of clopidogrel metabolite in plasma and platelet inhibition status.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 1, 2010
CompletedFirst Submitted
Initial submission to the registry
September 26, 2010
CompletedFirst Posted
Study publicly available on registry
September 28, 2010
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2012
CompletedSeptember 28, 2010
May 1, 2010
1.3 years
September 26, 2010
September 27, 2010
Conditions
Interventions
BLOOD SAMPLE WILL BE COLLECTED FOR 3 KINDS OF TESTS
Eligibility Criteria
THE RESEARCH WILL INVOLVE PATIENTS THAT TAKE CLOPIDOGREL AND READY TO GIVE INFORMED CONSENT FOR GENETIC TESTING.
You may qualify if:
- \> 18 OLD PATIENTS
- THAT TAKE CLOPIDOGREL MORE THAN 1 WEEK
You may not qualify if:
- PREGNANCY
- CHRONIC LIVER DISEASES
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Assaf Harofeh Medical Center
Zeriffin, Israel, Israel
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER GOV
Study Record Dates
First Submitted
September 26, 2010
First Posted
September 28, 2010
Study Start
September 1, 2010
Primary Completion
January 1, 2012
Last Updated
September 28, 2010
Record last verified: 2010-05